Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01375660 · ClinicalTrials.gov registry record · NA
D Vitamin Intervention in VA
A NA study of Impaired Glucose Tolerance and Vitamin D Insufficiency, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- NA
- Development phase
- 205
- Enrollment target
- 1
- Study location
NCT01375660: Completed NA study of Impaired Glucose Tolerance and Vitamin D Insufficiency, sponsored by US Department of Veterans Affairs.
NCT01375660 is a NA study of Impaired Glucose Tolerance and Vitamin D Insufficiency that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 205 participants, above the 74-participant average among 13 other Impaired Glucose Tolerance trials with a reported enrollment target (177% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01375660, a NA study of Impaired Glucose Tolerance and Vitamin D Insufficiency, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- NA
- Development phase
- 205 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will supplement African American male (AAM) veterans at risk for diabetes and newly diagnosed T2DM with vitamin D (low or higher dose) and evaluate whether vitamin D helps to improve early markers of diabetes. The study will be done at Veteran Administration Medical Center in Chicago.
Primary Outcome
Oral glucose insulin sensitivity = index of insulin sensitivity, higher index means higher insulin sensitivity. Low insulin sensitivity means high insulin resistance and high risk of type 2 diabetes mellitus. It is calculated by a special formula using insulin and glucose measured in Oral Glucose Tolerance test. The primary outcome was the change in oral glucose insulin sensitivity (OGIS, from oral glucose tolerance test) after 12 months of treatment calculated as OGIS at 12-months minus OGIS b
Conditions Studied
Interventions
- DRUG Placebo
- DRUG 50K vitamin D2
Study Locations (1)
Illinois
- Jesse Brown VA Medical Center, Chicago, IL - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2011-05 |
| Est. Completion | 2014-11 |
| Phase | NA |
What the finished NCT01375660 record still lists
NCT01375660 is an interventional study that assigns participants to a tested intervention. The registered 205 participants enrollment target is mid-sized for trials with a published cap, above the 74-participant average among 13 other Impaired Glucose Tolerance trials with a reported enrollment target (177% higher).
The record links to 3 conditions, with Impaired Glucose Tolerance appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01375660 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT01375660 about?
NCT01375660 is a clinical study titled "D Vitamin Intervention in VA". This study will supplement African American male (AAM) veterans at risk for diabetes and newly diagnosed T2DM with vitamin D (low or higher dose) and evaluate whether vitamin D helps to improve early markers of diabetes. The study will be done at Veteran Administration Medical Center in Chicago.
What is the current status of trial NCT01375660?
This trial is currently completed. It is a NA study. The enrollment target is 205 participants. The study started on 2011-05. Estimated completion is 2014-11.
What conditions does trial NCT01375660 study?
This clinical trial studies the following conditions: Impaired Glucose Tolerance, Vitamin D Insufficiency, Impaired Fasting Glucose.
What interventions are being tested in trial NCT01375660?
The interventions under investigation include: Placebo (DRUG), 50K vitamin D2 (DRUG).
Who is sponsoring clinical trial NCT01375660?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01375660 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Impaired Glucose Tolerance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01375660's enrollment target sits among peer trials
205 2nd of 13 the highest of 13 other Impaired Glucose Tolerance trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Impaired Glucose Tolerance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of an Obesogenic Lifestyle in Recreationally Active, Young Adults
RECRUITING · NA
-
CGM and Lifestyle Changes in Patients With Impaired Glucose Tolerance
RECRUITING · NA
-
Night Owl Metabolism
RECRUITING · NA
-
Improving Autonomic Function and Balance in Diabetic Neuropathy
ACTIVE NOT RECRUITING · NA
-
Effect of Dietary Glycemic Index on Beta-cell Function
COMPLETED · NA
-
Sucralose, Stevia, Gut Microbiome and Glucose Metabolism
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03457493 · 205 participants · Phase 1
The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
- NCT05134857 · 205 participants · Phase 2
The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study
- NCT05181891 · 205 participants · Phase 2
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
- NCT05283811 · 205 participants · NA
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia